Mr. Norbert Roland Manz is a pharmacist who is specialized in Oncology in Parma, Ohio. Patients can reach him at 12301 Snow Rd, Parma or contact him on 216-265-6855. Active license number of Mr. Norbert Roland Manz is 03215401 for Oncology in Ohio. Mr. Norbert Roland Manz is a licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Complete Profile:
Mr. Norbert Roland Manz speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Mr. Norbert Roland Manz
Specialization:
Oncology
Credentials:
RPH.
Gender:
Male
Location:
12301 Snow Rd, Parma, Ohio, 44130-1002
Phone:
216-265-6855
Fax:
216-265-6856
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Mr. Norbert Roland Manz are as mentioned below.
NPI Number:
1306976444
NPI Enumeration Date:
07 Mar, 2007
NPI Last Update On:
08 Jul, 2007
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Mr. Norbert Roland Manz are as mentioned below.
Specialization
License Number
State
Status
Oncology
03215401
Ohio
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
7562 Farnum Ave, Cleveland, Ohio
Zip:
44130-6444
Phone Number:
216-265-6855
Fax Number:
216-685-6856
Patients can reach Mr. Norbert Roland Manz at 12301 Snow Rd, Parma, Ohio or can call on phone at 216-265-6855.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 March, 2024.